Preventing certain types of kidney stones. It also may be used for other conditions as determined by your doctor.
Urocit-K is a urinary alkalinizing agent. It works by neutralizing some of the acid in the urine, which helps reduce the formation of crystals.
Submit your review
Applies to potassium citrate: oral patch extended release, oral solution, oral tablet, oral tablet extended release
As well as its needed effects, potassium citrate (the active ingredient contained in Urocit-K) may cause unwanted side effects that require medical attention.
If any of the following side effects occur while taking potassium citrate, check with your doctor immediately:
Incidence not known
Abdominal or stomach discomfort
If any of the following symptoms of overdose occur while taking potassium citrate, get emergency help immediately:
Symptoms of overdose
Abdominal or stomach pain
numbness or tingling in the hands, feet, or lips
shortness of breath
weakness or heaviness of the legs
Treatment with extended release potassium citrate should be added to a regimen that limits salt intake (avoidance of foods with high salt content and of added salt at the table) and encourages high fluid intake (urine volume should be at least two liters per day). The objective of treatment with Urocit®-K is to provide Urocit®-K in sufficient dosage to restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6.0 or 7.0. Monitor serum electrolytes (sodium, potassium, chloride and carbon dioxide), serum creatinine and complete blood counts every four months and more frequently in patients with cardiac disease, renal disease or acidosis. Perform electrocardiograms periodically. Treatment should be discontinued if there is hyperkalemia, a significant rise in serum creatinine or a significant fall in blood hemocrit or hemoglobin. Severe Hypocitraturia In patients with severe hypocitraturia (urinary citrate < 150 mg/day), therapy should be initiated at a dosage of 60 mEq/day (30 mEq two times/day or 20 mEq three times/day with meals or within 30 minutes after meals or bedtime snack). Twenty-four hour urinary citrate and/or urinary pH measurements should be used to determine the adequacy of the initial dosage and to evaluate the effectiveness of any dosage change. In addition, urinary citrate and/or pH should be measured every four months. Doses of Urocit®-K greater than 100 mEq/day have not been studied and should be avoided. Mild to Moderate Hypocitraturia In patients with mild to moderate hypocitraturia (urinary citrate > 150 mg/day) therapy should be initiated at 30 mEq/day (15 mEq two times/day or 10 mEq three times/day within 30 minutes after meals or bedtime snack). Twenty-four hour urinary citrate and/or urinary pH measurements should be used to determine the adequacy of the initial dosage and to evaluate the effectiveness of any dosage change. Doses of Urocit®-K greater than 100 mEq/day have not been studied and should be avoided.